Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies

Inclusion Criteria: * Patients must have pathologically or cytologically confirmed solid or hematologic cancers. OR * Patient is receiving alpelisib for PIK3CA-Related Overgrowth Spectrum disorder. * Female and male aged 18 to 85 years, inclusively, at the time of Week 0/Day 1 of treatment. * Patients must have a therapy-related CTCAE grade 2/3 (See Appendix A)cutaneous adverse event defined as any cutaneous reaction listed below and blood eosinophil counts of at least .3 K/mcl. * Rash maculo-papular * Bullous dermatitis * Pruritus * Urticaria * Eczema * Patients must plan to continue on culprit drugs (cancer patients). * Patients planning to receive alpelisib indicated for PIK3CA-Related Overgrowth Spectrum disorder OR patients receiving immunotherapy and/or targeted therapy, including but not limited to the following agents, will be eligible for inclusion: * Immunotherapies: ipilimumab, nivolumab, pembrolizumab, avelumab, durvalumab, atezolizumab tremelimumab. * Targeted therapies: trastuzumab, pertuzumab, alpelisib, osimertinib, everolimus, temsirolimus, sorafenib, regorafenib. * Patients using topicals/orals for indication of skin rash/pruritus for at least 7 days should continue using these drugs for the study duration * Adequate bone marrow, liver and renal function: * Total bilirubin ≤ 1.5 x the upper limit of normal (ULN) * Alanine aminotransferase (ALT) and aspartate amino-transferase (AST) ≤ 2.5 x ULN (≤ 5 x ULN for subjects with liver involveme…